| Literature DB >> 36046660 |
Lili Xu1,2, Yang Jiao2, Weiliang Cui2, Bing Wang2, Dongxiao Guo2, Fei Xue2, Xiangrong Mu2, Huifen Li1, Yongqiang Lin2, Huibin Lin3.
Abstract
Background: Naolingsu capsule (NLSC) is a well-known traditional Chinese medicine (TCM) prescription in China. It is widely used to treat neurasthenia, insomnia, cardiovascular and cerebrovascular disease, and other diseases. However, its inalienable chemical groups have not been carried out.Entities:
Year: 2022 PMID: 36046660 PMCID: PMC9424029 DOI: 10.1155/2022/1429074
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.594
MS parameters of the fourteen components.
| Analytes |
| m/ | m/ | Dp (V) | Ce (eV) |
|---|---|---|---|---|---|
| DA | 11.32 | 482.4 | 437.6/421.0q | −235 | −54/−54 |
| PAC | 11.73 | 481.4 | 437.5/419.3q | −265 | −48/−48 |
| ATA | 12.60 | 527.4 | 465.2/405.4q | −300 | −54/−54 |
| XS | 4.30 | 400.2 | 238.2/161.2q | −40 | −19/−18 |
| XZ | 5.04 | 237.9 | 208.0/196.0q | −40 | −22/−21 |
| JA | 8.16 | 1205.7 | 1072.9/749.8q | −220 | −60/−75 |
| JB | 8.96 | 1042.7 | 911.7/749.7q | −220 | −50/−60 |
| MPA | 10.49 | 341.1 | 206.0/178.1q | −110 | −35/−40 |
| RD | 2.45 | 685.3 | 262.1/178.9q | −110 | −28/−33 |
| GRF | 8.14 | 799.6 | 637.7/475.4q | −220 | −37/−50 |
| GRG | 6.69 | 799.6 | 637.7/475.4q | −220 | −37/−50 |
| GRR | 6.69 | 945.6 | 799.7/637.6q | −220 | −44/−53 |
| GRB | 8.96 | 1107.7 | 945.6/782.5q | −220 | −60/−65 |
| PX | 5.04 | 567.2 | 417.2/297.1q | −100 | −41/−35 |
| Ion source (GS1) | 50 | ||||
| Ion source (GS2) | 50 | ||||
| Curtain gas (CUR) | 30 | ||||
| Collision gas (CAD) | 8 | ||||
| EP | −14 | ||||
| CXP | −22 |
qProduct ion used for quantification.
Figure 1HPLC-DAD fingerprint chromatograms of NLSCs (R) and 12 medicinal materials.
Figure 2HPLC fingerprint of NLSC.
The results of linearity, LOD, and LOQ.
| Analytes | Regression equation |
| Linearity range | LOD | LOQ |
|---|---|---|---|---|---|
| NA |
| 0.9998 | 1.26–31.44a | 0.12a | 0.39a |
| CA |
| 0.9999 | 1.60–39.84a | 0.20a | 0.40a |
| DS |
| 0.9984 | 3.28–83.08a | 0.62a | 3.05a |
| EA |
| 0.9998 | 1.62–40.72a | 0.31a | 1.02a |
| EB |
| 0.9996 | 1.41–35.20a | 0.26a | 0.88a |
| EC |
| 0.9985 | 3.42–60.72a | 0.23a | 0.76a |
| ICA |
| 0.9994 | 3.71–93.84a | 0.56a | 1.86a |
| SA |
| 1.0000 | 6.95–173.88a | 0.33a | 1.11a |
| BSI |
| 0.9999 | 3.13–53.44a | 0.20a | 0.67a |
| SSA |
| 0.9999 | 3.25–56.24a | 0.21a | 0.70a |
| SSB |
| 0.9998 | 3.62–65.44a | 0.26a | 0.82a |
| DA |
| 0.9999 | 9.84–984.0b | 0.74b | 3.46b |
| PAC |
| 1.0000 | 11.16–1115.5b | 1.67b | 5.58b |
| ATA |
| 0.9992 | 9.14–1828.0b | 0.68b | 3.28b |
| XS |
| 0.9997 | 5.10–2040.0b | 0.38b | 1.28b |
| XZ |
| 0.9996 | 4.70–470.0b | 0.70b | 3.35b |
| JA |
| 0.9997 | 24.74–989.4b | 0.92b | 3.09b |
| JB |
| 0.9999 | 11.11–2223.6b | 0.33b | 1.11b |
| MPA |
| 0.9996 | 5.54–553.6b | 0.42b | 1.39b |
| RD |
| 1.0000 | 5.36–2144.0b | 0.82b | 1.34b |
| GRF |
| 0.9994 | 4.54–908.0b | 0.34b | 1.13b |
| GRG |
| 0.9991 | 5.06–2025.0b | 0.38b | 1.26b |
| GRR |
| 0.9998 | 11.39–2277.6b | 0.43b | 3.84b |
| GRB |
| 0.9978 | 11.14–2229.0b | 0.33b | 1.11b |
| PX |
| 0.9996 | 11.09–2217.6b | 0.33b | 1.11b |
a μg/ml (data acquired by HPLC-DAD). bng/ml (data acquired by LC-MS/MS).
Figure 3Results of heat map analysis on the determination of HPLC-DAD (a) and LC-MS/MS (b).
Figure 4PCA-3D score plot on the first three principal components.
Figure 5PLS-DA diagram of 24 batches of NLSC sample.
Figure 6VIP diagram of 24 batches of NLSC sample.